Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian Cancer

FDA also approved the Myriad myChoice® CDx as a companion diagnostic for olaparib
13 May 2020
Anticancer agents & Biologic therapy;  Gynaecologic malignancies;  Personalised medicine

On 8 May 2020, the US Food and Drug Administration (FDA) expanded the indication of olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) to include its combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. 

FDA also approved the Myriad myChoice® CDx (Myriad Genetic Laboratories, Inc.) as a companion diagnostic for olaparib.

Efficacy of this new indication was investigated in PAOLA-1 (NCT03737643), a randomised, double-blind, placebo-controlled, multicentre trial comparing olaparib with bevacizumab versus placebo plus bevacizumab in patients with advanced high-grade epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer following first-line platinum-based chemotherapy and bevacizumab.

Randomisation was stratified by first-line treatment outcome and tumour BRCA mutation status, determined by prospective local testing. All available clinical samples were retrospectively tested with Myriad myChoice® CDX test.

Patients were randomised (2:1) to receive olaparib tablets 300 mg orally twice daily in combination with bevacizumab (n=537) 15 mg/kg every three weeks or placebo plus bevacizumab (n=269). Patients continued bevacizumab in the maintenance setting and started olaparib after a minimum of 3 weeks and up to a maximum of 9 weeks following their last chemotherapy dose. Olaparib was continued for up to 2 years or until disease progression or unacceptable toxicity.

The major efficacy outcome measure was investigator-assessed progression-free survival (PFS) evaluated according to RECIST v1.1. An additional efficacy endpoint was overall survival (OS). Estimated median PFS in the subgroup of 387 patients with HRD-positive tumours was 37.2 months in the olaparib with bevacizumab arm and 17.7 months in the placebo plus bevacizumab arm (hazard ratio 0.33; 95% confidence interval 0.25-0.45). Results from a blinded independent review of PFS were consistent with the investigator-assessed PFS analysis. The OS data were not mature.

The most common adverse reactions in the olaparib with bevacizumab treatment (≥10% of patients) were nausea, fatigue (including asthenia), anaemia, lymphopenia, vomiting, diarrhoea, neutropenia, leukopenia, urinary tract infection, and headache.

The recommended olaparib dose is 300 mg taken orally twice daily, with or without food. When used with olaparib, the recommended bevacizumab dose is 15 mg/kg intravenously every three weeks.

Full prescribing information for LYNPARZA is available here.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

FDA granted this application priority review and orphan product designation.  

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Centre of Excellence Project Facilitate. 

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings